Company profile
Suninflam Inc.
Privately held: no public share price (Not on the IBD Terminal roster. Clinical-stage biopharmaceutical company developing SIF001 (monoclonal antibody) for epilepsy (NCT07051629). Tracked as a private company in Citeline Insights and business-registry listings (bizapedia); no evidence of a stock listing found. No confirmed relationship established to the similarly-named "Suninflam Ltd." (Shenzhen) entity in D&B records -- not asserted. Sources: https://clinicaltrials.gov/study/NCT07051629 ; https://insights.citeline.com/companies/suninflam-inc/ ; https://www.bizapedia.com/ca/suninflam-inc.html ; https://clinconnect.io/trials/NCT07051629 Entity resolved by asset-pipeline-v2.)
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
| Phase 1 | Galectin-3Monoclonal antibody | Epilepsy |
Upcoming events
Unlock the company readout calendar
Research includes estimated primary-completion dates, earnings report dates, and 'What to watch' trial analysis across this company’s pipeline.
Financial reports
Unlock sourced financial history
Research includes quarterly, interim and annual revenue, R&D, cash and burn figures linked to the underlying company reports.